DCF Valuation

Medline Inc. Class A Common Stock (MDLN) DCF Valuation — Is MDLN overvalued?

The estimated DCF fair value of one Medline Inc. Class A Common Stock (MDLN) share is $35.66. Compared to the current market price of $36.66, the stock is overvalued by 2.7%.

DCF fair value

$35.66

Market price

$36.66

Upside / downside

−2.7%

Run the full interactive DCF model →

Prefer the inverse question? See what growth rate the market is pricing into MDLN

Medline Inc. Class A Common Stock (MDLN) DCF valuation FAQ

What is the DCF fair value of Medline Inc. Class A Common Stock (MDLN)?

The discounted-cash-flow model estimates the intrinsic fair value of one Medline Inc. Class A Common Stock (MDLN) share at $35.66, based on a 10-year projection of its cash flows converging to Damodaran industry averages.

Is Medline Inc. Class A Common Stock (MDLN) overvalued or undervalued?

Against the current market price of $36.66, the DCF fair value of $35.66 implies MDLN is overvalued by 2.7%.

How is the MDLN DCF value calculated?

It is a 10-year discounted-cash-flow estimate built from Medline Inc. Class A Common Stock's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when Medline Inc. Class A Common Stock files a new quarterly or annual report.

How this MDLN valuation is built

The model projects ten years of Medline Inc. Class A Common Stock's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing Medline Inc. Class A Common Stock's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.

WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.

The market price refreshes daily; the DCF fair value updates when Medline Inc. Class A Common Stock files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-06.